0000899243-18-029124.txt : 20181116
0000899243-18-029124.hdr.sgml : 20181116
20181116160032
ACCESSION NUMBER: 0000899243-18-029124
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181115
FILED AS OF DATE: 20181116
DATE AS OF CHANGE: 20181116
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ROGERS MICHAEL W
CENTRAL INDEX KEY: 0001244159
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51122
FILM NUMBER: 181189836
MAIL ADDRESS:
STREET 1: C/O KERYX BIOPHARMACEUTICALS INC
STREET 2: ONE MARINA PARK DRIVE
CITY: BOSTON
STATE: MA
ZIP: 02210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: EyePoint Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001314102
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
IRS NUMBER: 262774444
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 480 PLEASANT STREET
STREET 2: SUITE B300
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 617-926-5000
MAIL ADDRESS:
STREET 1: 480 PLEASANT STREET
STREET 2: SUITE B300
CITY: WATERTOWN
STATE: MA
ZIP: 02472
FORMER COMPANY:
FORMER CONFORMED NAME: pSivida Corp.
DATE OF NAME CHANGE: 20080619
FORMER COMPANY:
FORMER CONFORMED NAME: pSivida LTD
DATE OF NAME CHANGE: 20050111
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-11-15
0
0001314102
EyePoint Pharmaceuticals, Inc.
EYPT
0001244159
ROGERS MICHAEL W
C/O EYEPOINT PHARMACEUTICALS, INC.
480 PLEASANT STREET
WATERTOWN
MA
02472
1
0
0
0
Common Stock
2018-11-15
4
M
0
100000
1.13
A
112500
D
Employee Stock Option (right to buy)
1.13
2018-11-15
4
M
0
100000
0.00
D
2009-11-18
2018-11-18
Common Stock
100000
0
D
Consists of (i) 100,000 shares of common stock, par value $0.001 per share, of EyePoint Pharmaceuticals, Inc. (the "Company") acquired upon exercise of the stock option as described above and (ii) 12,500 shares of common stock of the Company underlying certain deferred stock units ("DSUs") previously awarded to the reporting person, with each DSU representing the right to receive one share of common stock of the Company. These DSUs vested in full on June 27, 2018 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986,
/s/ John Mercer, Attorney-in-Fact
2018-11-16